326 related articles for article (PubMed ID: 35467558)
21. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
Meyer A; Fumery M; Peyrin-Biroulet L; Filippi J; Altwegg R; Bouhnik Y; Serrero M; Laharie D; Roblin X; Nachury M; Abitbol V; Cadiot G; Nancey S; Allez M; Gilletta C; Vuitton L; Savoye G; Nahon S; Bourrier A; Buisson A; Bouguen G; Bourreille A; Viennot S; Carbonnel F; Amiot A
Scand J Gastroenterol; 2022 Dec; 57(12):1454-1462. PubMed ID: 35819361
[TBL] [Abstract][Full Text] [Related]
22. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
23. Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease.
Kappelman MD; Adimadhyam S; Hou L; Wolfe AE; Smith S; Simon AL; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett LE; Haynes K; Selvan M; Ma Q; Nair V; Burris J; Dorand JE; Dawwas GK; Lewis JD; Long MD
Am J Gastroenterol; 2023 Apr; 118(4):674-684. PubMed ID: 36508681
[TBL] [Abstract][Full Text] [Related]
24. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
[TBL] [Abstract][Full Text] [Related]
25. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn's Disease Initiating Vedolizumab Versus Ustekinumab.
Kappelman MD; Lewis JD; Zhang X; Lin FC; Weisbein L; Chen W; Burris J; Dorand JE; Parlett LE; Haynes K; Nair V; Kaul AF; Dobes A; Long MD
Dig Dis Sci; 2023 Aug; 68(8):3413-3420. PubMed ID: 37115362
[TBL] [Abstract][Full Text] [Related]
26. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
27. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
Gisbert JP; Chaparro M
Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
[TBL] [Abstract][Full Text] [Related]
28. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
[TBL] [Abstract][Full Text] [Related]
30. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
[TBL] [Abstract][Full Text] [Related]
31. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
Chapuis-Biron C; Kirchgesner J; Pariente B; Bouhnik Y; Amiot A; Viennot S; Serrero M; Fumery M; Allez M; Siproudhis L; Buisson A; Pineton de Chambrun G; Abitbol V; Nancey S; Caillo L; Plastaras L; Savoye G; Chanteloup E; Simon M; Dib N; Rajca S; Amil M; Parmentier AL; Peyrin-Biroulet L; Vuitton L;
Am J Gastroenterol; 2020 Nov; 115(11):1812-1820. PubMed ID: 33156100
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
35. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
[TBL] [Abstract][Full Text] [Related]
36. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
[TBL] [Abstract][Full Text] [Related]
38. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
39. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
40. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]